Renaissance Technologies LLC Increases Position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT)

Renaissance Technologies LLC boosted its position in EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) by 112.5% during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 152,800 shares of the company’s stock after acquiring an additional 80,900 shares during the quarter. Renaissance Technologies LLC owned 0.29% of EyePoint Pharmaceuticals worth $1,329,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors have also added to or reduced their stakes in the company. Ghisallo Capital Management LLC bought a new position in shares of EyePoint Pharmaceuticals during the 4th quarter valued at about $2,511,000. Artia Global Partners LP purchased a new position in shares of EyePoint Pharmaceuticals during the fourth quarter worth approximately $1,156,000. PFM Health Sciences LP bought a new stake in shares of EyePoint Pharmaceuticals in the 4th quarter worth approximately $3,949,000. Sierra Summit Advisors LLC purchased a new stake in shares of EyePoint Pharmaceuticals in the 4th quarter valued at $523,000. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new position in shares of EyePoint Pharmaceuticals during the 4th quarter valued at $3,166,000. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Insider Transactions at EyePoint Pharmaceuticals

In related news, Director David R. Guyer sold 11,625 shares of the firm’s stock in a transaction on Friday, July 12th. The stock was sold at an average price of $10.06, for a total value of $116,947.50. Following the transaction, the director now directly owns 1,850 shares of the company’s stock, valued at approximately $18,611. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 4.74% of the company’s stock.

EyePoint Pharmaceuticals Trading Up 3.1 %

Shares of EyePoint Pharmaceuticals stock opened at $8.63 on Friday. The business has a fifty day simple moving average of $8.58 and a two-hundred day simple moving average of $11.86. The firm has a market capitalization of $449.48 million, a P/E ratio of -4.74 and a beta of 1.57. EyePoint Pharmaceuticals, Inc. has a 12 month low of $5.67 and a 12 month high of $30.99.

EyePoint Pharmaceuticals (NASDAQ:EYPT) last announced its earnings results on Wednesday, August 7th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.03). The company had revenue of $9.48 million for the quarter, compared to analysts’ expectations of $11.61 million. EyePoint Pharmaceuticals had a negative net margin of 172.29% and a negative return on equity of 43.24%. Analysts predict that EyePoint Pharmaceuticals, Inc. will post -2.33 earnings per share for the current year.

Wall Street Analyst Weigh In

EYPT has been the subject of several analyst reports. Chardan Capital restated a “buy” rating and set a $28.00 price target on shares of EyePoint Pharmaceuticals in a research report on Friday, June 28th. StockNews.com upgraded EyePoint Pharmaceuticals to a “sell” rating in a report on Saturday, September 21st. Jefferies Financial Group initiated coverage on EyePoint Pharmaceuticals in a research note on Wednesday, August 28th. They issued a “buy” rating and a $15.00 target price on the stock. HC Wainwright reissued a “buy” rating and set a $30.00 target price on shares of EyePoint Pharmaceuticals in a research note on Thursday, June 27th. Finally, JPMorgan Chase & Co. dropped their price target on EyePoint Pharmaceuticals from $32.00 to $29.00 and set an “overweight” rating for the company in a research note on Tuesday, August 13th. One research analyst has rated the stock with a sell rating and eight have given a buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $30.57.

EyePoint Pharmaceuticals Company Profile

EyePoint Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, engages in developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases. The company's pipeline leverages its proprietary bioerodible Durasert E technology for sustained intraocular drug delivery.